Szczegóły publikacji
Opis bibliograficzny
Elevated carbonylated proteins are associated with major cardiovascular events in patients with chronic coronary syndrome: a cohort study / Krystian Mróz, Elżbieta Paszek, Mateusz BARAN, Michał Ząbczyk, Saulius Butenas, Anetta Undas // Kardiologia Polska = Polish Heart Journal ; ISSN 0022-9032. — 2024 — vol. 82 no. 7–8, s. 708–715. — Bibliogr. s. 714–715, Abstr. — Publikacja dostępna online od: 2024-05-09
Autorzy (6)
- Mróz Krystian
- Paszek Elżbieta
- AGHBaran Mateusz
- Ząbczyk Michał
- Butenas Saulius
- Undas Anetta
Słowa kluczowe
Dane bibliometryczne
| ID BaDAP | 158169 |
|---|---|
| Data dodania do BaDAP | 2025-02-14 |
| Tekst źródłowy | URL |
| DOI | 10.33963/v.phj.100609 |
| Rok publikacji | 2024 |
| Typ publikacji | artykuł w czasopiśmie |
| Otwarty dostęp |  |
| Creative Commons | |
| Czasopismo/seria | Kardiologia Polska = Polish Heart Journal |
Abstract
Background: Protein carbonylation is reported in atherosclerosis, but its predictive value is unknown. Aims: We evaluated plasma carbonylated protein (PC) levels in association with clinical outcomes in coronary artery disease (CAD) in long-term follow-up. Methods: In patients with advanced stable CAD, we assessed plasma PC content along with fibrin clot properties, i.e., permeability (Ks) and clot lysis time, and its determinants: plasminogen activator inhibitor-1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor. We recorded a composite of myocardial infarction, ischemic stroke, systemic embolism, and cardiovascular death during a follow-up of 8.3 (1.8) years. Results: The analysis involved 178 patients aged 64.0 (57.0-70.0) years. The baseline PC content was 2.9 (2.2-3.7) nmol/mg protein and was elevated above the reference value obtained for a control group (2.03 nmol/mg protein) in 82.6% of patients. In linear regression models, high PC adjusted for age was associated with lower Ks, longer clot lysis time, and elevated PAI-1 and thrombin-activatable fibrinolysis inhibitor. Baseline PC was 48% higher in patients with the composite endpoint (n = 67, 37.6%) compared with others (P <0.001). Patients with PC in the highest quartile (3.7-5.1 nmol/mg protein) were more likely to develop the composite endpoint compared to the lowest quartile (hazard ratio [HR] 4.9; 95% confidence interval, 2.1-11.3; P <0.001). Conclusions: This is the first study showing that in CAD the extent of protein carbonylation, in part via its antifibrinolytic effects, predisposes to cardiovascular events in long-term follow-up, highlighting the role of persistent oxidative protein modifications in atherosclerotic vascular disease.
